News

GEN - Genetic Engineering and Biotechnology News3d
Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths
Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...
Investor's Business Daily on MSN3d
Sarepta Catapults 20% On Restructuring Plans In The Wake Of Two Patient Deaths
Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two ...
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Fierce Biotech2d
UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Sarepta Therapeutics crisis is huge blow to Duchenne families, company
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
BioSpace3d
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...